Annual results for Alliance Boots shows double digit growth

Alliance Boots filed its annual financial results today. Some image rights reserved by [F]oxymoron
Alliance Boots filed its annual financial results today. Some image rights reserved by [F]oxymoron

Alliance Boots, the pharmaceutical and beauty products group, has reported strong trading figures for the year ending March 31 2012.

Revenues and trading profits for 2011-12 were both up for Alliance Boots this year with the former seeing a boost of 18.4% (to £23,009m) and the latter increasing by 12.4% (to £1,195m).

Strong cash generation from operations was pin pointed as significant in company statements. Cash generated from operations for the year was reported as £1,601m and during the 2011-12 financial year Boots Alliance invested £262m in capital expenditure.

Results for the pharmaceutical wholesale division of Alliance Boots were stronger than those for the Beauty division. Pharmaceutical wholesale revenues were up 27.9% on the previous year and trading profit was up 24.7%.

Alliance boots works closely with pharmaceutical manufacturers in the UK, helping them to increase control of their product distribution and to outsource non-core activities. Alliance Boots’ services to manufacturers include pre-wholesale and contract logistics.

Looking forward, Alliance Boots’ executive chairman, Stefano Pessina commented: “In the coming year, we expect the economic environment to remain difficult with continuing pressure on both consumer and governmental expenditure.  This will generate both challenges and new opportunities for us.”

He continued, “We are confident about our future prospects and ability to pursue profitable growth, both organically and through further international expansion.”

Leave a Reply

You must be logged in to post a comment.

Related Sector Article

The Office of Fair Trading has accused pharmaceuticals giant GlaxoSmithKline of market "abuse".

Ribena, GlaxoSmithKline

Related Sector Article

GW Pharmaceuticals, the biopharmaceutical company focused on developing cannabis-based therapeutics, has announced that Sativex, its treatment for spasticity in Multiple Sclerosis, has been determined by Advisory Council on Misuse of Drugs (ACMD) that has a low potential for abuse and low risk of diversion.

Marijuana plantation - photo courtesy of West Midlands Police

Related Topic Article

Jaguar Land Rover, the UK’s leading luxury car producer, experienced its best ever April last month with sales of 28,503 cars, a 12% increase on the same period last year.

Jaguar XF 2013

Related Topic Article

Electric car manufacturer Tesla Motors has reported its first quarterly profit, demonstrating a growing interest in low carbon performance vehicles in the US.

A photo taken at the Tesla Motors Model S deliver ceremony event.

UPCOMING EVENTS

  • LMJ MPU 300x250 260313
  • ERP Connect December 2013

Reports

More reports

Advert

Manufacturing Jobs

View all jobs

Advertisements





Advertisement

Tracking